Against the backdrop of a clearly weakening economy, Evonik showed a solid performance in the third quarter. Although sales volumes sold declined, revenues increased by 26% year-on-year to €4.88 billion due to price increases. That way, higher variable costs were successfully passed on. Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) only declined by 5% to €615 million. “Despite the increasingly difficult environment, we remain confident of achi...